Polyneuron’s surgical strike

Why Sofinnova Partners, NEA backed Polyneuron's $22.6M series A

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A

Read the full 350 word article

User Sign In